Clinical efficacy of @entity205 a neoral in the treatment of paediatric @entity1988 with heavy XXXX .

@entity1 @entity644 @entity137 @entity870 @entity786 @entity1988 @entity205 @entity134 @entity617
@entity205 (CsA) was introduced in recent years for the treatment of @entity1988 in @entity1 with @entity134 resistance or in those with severe corticosteroid @entity137 . Our previous study on paediatric @entity1 showed that Neoral (a new microemulsion formulation) had better bioavailability than @entity870 capsules. To evaluate the clinical efficacy of Neoral in @entity1 with @entity1988 compared with conventional therapy, we performed an open randomized study on 40 @entity1 , ranging from 9 to 14 yr old, with class III-V @entity1988 and heavy @entity644 . They were randomly assigned to either Neoral (5 mg/kg/day), administered q.12.h, or @entity617 (2 mg/kg/day) plus @entity786 (2 mg/kg/day) for 1 yr. Both groups showed a significant decrease in @entity644 (Neoral: 4.62 +/- 1.93 to 0.35 +/- 0.29 g/day, P < 0.05; @entity617 plus @entity786 : 4.52 +/- 1.86 to 0.62 +/- 0.21 g/day, P < 0.01). The CH50 haemolytic assay titre decreased after 1 yr of Neoral treatment (26.5 +/- 0.9 to 21.4 +/- 2.2 U/ml, P < 0.05). Serum C3 and anti-double-stranded (ds) DNA antibody levels also fell with Neoral (C3: 86.2 +/- 6.8 to 76.3 +/- 4.5 mg/dl; anti-ds DNA antibodies: 14.1 +/- 3.2 to 8.2 +/- 1.4 IU/ml, P < 0.05). The Neoral group had a significant increase in growth rate over the @entity617 plus @entity786 group (8.2 +/- 1.1 cm/yr vs 2.7 +/- 0.6 cm/yr, P < 0.01) with improvement of growth status. During the study period, @entity1 tolerated Neoral well with no significant changes in renal function, liver function or lipid profile. Our study implies that Neoral appears to be effective in suppressing @entity644 . Neoral should be regarded as being adjunctive therapy, perhaps with a @entity134 -sparing effect, in paediatric @entity1988 . However, its long-term use awaits further studies.
